Manager TitleAgeSince
Chief Executive Officer 71 01/01/2016
Director of Finance/CFO 71 01/04/2017
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 64 01/01/2018
Director/Board Member 71 01/01/2018
Director/Board Member 52 21/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
-31.03%-40.43% - - 64.67K
+2.35%+2.74%+33.41%+79.20% 56.54B
-0.21%-7.38%+25.34%+63.02% 53.6B
-2.44%+1.40%-15.74%-16.80% 22.91B
-2.85%-7.78%-8.09%+346.36% 21.37B
+2.49%-0.92%+20.31%-12.15% 20.27B
+0.79%-1.06%+29.29%-33.32% 17.56B
+0.58%-5.88%+16.30%+540.37% 14.75B
-5.25%-4.23%+46.41%+169.05% 13.33B
+3.41%-6.61%+163.08%+280.43% 13.53B
Average -3.22%-3.79%+34.48%+157.35% 25.98B
Weighted average by Cap. +0.23%-2.96%+28.67%+119.98%
Logo Asarina Pharma AB
Asarina Pharma AB (publ), formerly Umecrine Mood, is a Sweden-based biotech company within area of women’s health. The Company’s main product is Sepranolone, a treatment for Premenstrual dysphoric disorder (PDD), a form of Premenstrual syndrome (PMS). Sepranolone (UC1010) is an endogenous compound occurring naturally in the brain. Sepranolone inhibits the effects of allopregnanolone, the steroid that causes PMDD. Moreover, Sepranolone is applicable for treatment of menstrual migraine. Additionally to clinical trials with sepranolone, the Company develops a sepranolone analog that is a similar substance, which allows for alternative administration. The Company conducts trials in Europe. The Company’s main shareholders are Kurma Biofund and The Foundation for Baltic and East European Studies.
Employees
6
  1. Stock Market
  2. Stocks
  3. ASAP Stock